People

I was fortunate during my anaesthetic training to complete a leadership and management module. This was at ST5 level of training at the William Harvey Hospital in Ashford, Kent. I believe my experience would highlight the benefits of this module and make the case for similar modules in anaesthetic training to be done with an agreed minimum standard. Background The ...

As Chair, together with Council, he will take forward the ambitious agenda set out in the GMC’s Corporate strategy 2014–17, hold the executive team to account and monitor its performance, and make sure the organisation maintains effective relationships with those who have a key interest in its work. Terence said: “I am committed to working with doctors, patients, empl...

Bunger, who holds a doctorate in health science, will oversee the development of clinical and health economic evidence supporting the adoption of SLF prosthetic vascular grafts, and brings an extensive repertoire of experience in clinical affairs including regulatory submission, clinical operations and clinical trial development to the company. She has previously led cli...

Subject to ratification by the membership at the Annual Meeting in Porto, Portugal, in September, Sebastian Debus from Hamburg, Germany will take over from current Secretary General Simon Parvin. Debus will be the 6th Secretary General of the Society. Until then, Debus will become a full member of the Executive Committee where important questions about the future of the ...

It was great to meet Dr Julie Edge and the Oxfordshire Paediatric Diabetes Team at the BMJ Awards recently. They were recognised for their work with primary schools overcoming the many barriers to diabetes care. Julie has recently published a review in Practical Diabetes covering some of the issues. (1) Photo of Diabetes Team of the Year The evening was in central L...

NEJM 8 Jan 2015 Vol 372 113 A vaccine that works really well is the best kind of medical intervention. But a vaccine that gives partial protection is a headache. Sanofi Pasteur has developed a tetravalent vaccine which is 60.8% protective against symptomatic dengue in children in Latin American countries where dengue is endemic. It is least effective in serotypes 1 and ...